EDAP TMS S.A. (FOCL) vs LivaNova (LIVN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
EDAP TMS S.A. (FOCL) has outperformed LivaNova (LIVN) over the past year, gaining 93.1% versus a gain of 46.6%. Over five years, LIVN leads with a -8.9% price change compared with -30.7% for FOCL. LivaNova is the larger company by market cap ($4.20 billion vs $197.8 million), about 21.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | FOCL | LIVN |
|---|---|---|
| Share price | $4.19 | $76.39 |
| Market cap | $197.84M | $4.20B |
| 1-day change | +1.58% | +0.63% |
| YTD return | +27.36% | +24.15% |
| 1-year return | +93.09% | +46.59% |
| 5-year return | -30.74% | -8.94% |
| P/E ratio (TTM) | — | 22.60 |
| Forward P/E | — | 16.31 |
| EPS (TTM) | $-1.39 | $3.38 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $1.39B |
| Revenue growth (YoY) | — | +10.74% |
| Net income (latest FY) | — | $-242.47M |
| Gross margin | — | 67.71% |
| Operating margin | — | 14.36% |
| Net margin | — | -17.47% |
| 52-week high | $6.40 | $85.76 |
| 52-week low | $1.75 | $48.82 |
| Distance from 52-week high | -34.53% | -10.93% |
| Analyst consensus | buy | buy |
| Avg. price target upside | +110.02% | +18.54% |
| Average volume | 115.89K | 648.38K |
| Shares outstanding | 47.22M | 54.93M |
| Employees | 289 | 3,300 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- LivaNova is about 21.2 times larger than EDAP TMS S.A. by market value ($4.20B vs $197.84M).
- FOCL has outperformed LIVN by 46.5 percentage points over the past year.
About EDAP TMS S.A.
FOCL stock →EDAP TMS S.A., doing business as FocalTherics, operates as a medical technology company that develops, manufactures, markets, and sells non-invasive therapeutic ultrasound and energy-based medical devices in Asia, France, the United States, and internationally. The company develops, manufactures, markets, and distributes non-invasive robotic HIFU systems for urology-related and other indications.
Health Care · Biotechnology: Electromedical & Electrotherapeutic Apparatus · 289 employees
About LivaNova
LIVN stock →LivaNova PLC, a medical technology company, designs, develops, manufactures, markets, and sells products, therapies, and services. The company operates in two segments, Cardiopulmonary and Neuromodulation.
Health Care · Biotechnology: Electromedical & Electrotherapeutic Apparatus · 3,300 employees
FOCL vs LIVN FAQ
Which is bigger, EDAP TMS S.A. or LivaNova?
LivaNova (LIVN) is larger, with a market capitalization of $4.20B compared with $197.84M for EDAP TMS S.A. (FOCL).
Which stock has performed better over the past year, FOCL or LIVN?
FOCL returned +93.09% over the past 12 months, compared with +46.59% for LIVN (price return, excluding dividends). Past performance does not predict future results.
Are EDAP TMS S.A. and LivaNova in the same industry?
Yes. Both are classified in the Biotechnology: Electromedical & Electrotherapeutic Apparatus industry within the Health Care sector.